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For non-adherent cell lines, viability determination was based on trypan blue 246 exclusion and/or determination of the % of cells displaying viable cell FSC vs SSC 247 parameters by flow cytometry analysis on cells negative after 7AAD staining. For adherent cells, viability determination was calculated based on the % of the OD obtained 249 in Crystal Violet staining assays at d+1 or d+3. Calculation was based on the formula %= 250 100x [OD for control (non electroporated) cell line/(OD for control (non electroporated) 251 cell line + OD for electroporated cell line). The "electroporation score" was calculated 252 based on cell viability (after normalization against the viability of non-transfected cells) 253 and transgene expression on d+1, and the score set to the formula "Viability 254 (%)*Expression (%)/F". A division factor (F=50 for adherent cell lines and F=100 for 255 non-adherent cell lines) was used in the score formula to fit the results in the graph scale.
257
Crystal Violet staining 258 259 To assess viability of adherent cell lines, cells were plated in triplicate in 96-well 260 microtiter plates immediately after electroporation. Cell viability was evaluated after 24 261 hours and cell expansion was analyzed at day+1 by crystal violet. The crystal violet 262 incorporation assay was performed by fixing the cells with ethanol for 10 min, followed 263 by staining them with 0.05% crystal violet in 20% ethanol for 10 min and solubilization 264 with methanol as reported (Faget et al., 2012) . The plate was read on a spectrophotometer 265 at 595 nm (SpectraMax 190, Molecular Devices, Sunnyvale, CA).
267
In vivo B16-F10 tumor model 268 269
B16F10 cells were electroporated with 4μg of pT3-NEO-EF1a-GFP and 1μg of 270 SB100x in buffer 1S, program P-020 of Lonza Nucleofactor II. As negative controls, we 271 electroporated cells only with pT3-NEO-EF1a-GFP. Each condition was plated in a 6-272 well plate. After reaching 80% confluence, G418 (Life Technologies) antibiotic was 273 added at 2,000μg/mL. The medium was changed every three days and the antibiotic 274 added. After selection with antibiotic or not, we injected 5x10 5 cells in the left flank of 275 C57BL/6 mice. After 15 days, we excised the tumor and plated the cells in 25cm 2 culture 276 flasks. After 24 hours, the culture medium was changed to eliminate non-adherent cells.
277
After 3 days, the cells were recovered and analyzed by flow cytometry for GFP Electroporated CD34+ cells were assayed in two different concentrations, 5x102 283 and 2x103 cells/well. The cells were concentrated in 300μL and then added in 1.1x 284 concentrated 3 mL Methocult™ H4034 (Stem Cell Technologies Inc., Vancouver, 285 Canada) then seeded 2 wells of a six-well plates, 1.1mL/well. Cells were cultivated for 286 three weeks at 37 °C in a humidified atmosphere supplemented 5% CO2 in incubator 287 300/3000 Series (Revco, Ohio, EUA). The colonies were identified and quantified using FACSCalibur® (BD Bioscience) was used to perform morphologic evaluation of 296 viability (FSC vs SSC) and GFP expression analysis. Cells were harvested the following 297 days after transfection and resuspended in PBS at a concentration of 105 cells/500uL. 7AAD staining (eBioscience cat. 00-6693) was performed immediately before FACS 299 acquisition following manufacturer instructions. Data were analyzed using the FlowJo 300 software (Tree Star). The hematopoietic progenitor CD34+ cells were evaluated for purity 301 by staining with anti-CD34-PE (clone 581, BD Biosciences). Variations of the pT3-Neo-EF1a-GFP construct were developed, such as the pT3-420 Neo plasmid, which confers resistance to G418 antibiotic and has restriction sites that 421 allow cloning of a second expression cassette. This plasmid was validated in G418 422 resistance assays using B16F10 cells (data not shown). The map for this plasmid is shown 423 in Figure S18 .
425
The use of primary cells derived from patients or healthy donors provides a more 426 accurate model for in vitro and in vivo experiments, and these cells can also be used in 427 cell therapy approaches to treat a large number of diseases. However, these applications 428 often depend on genetic modification, which is usually hard to perform in these cells. To 429 evaluate the performance of Chicabuffers in the gene transfer to these cells, we isolated 430 adipose tissue derived MSCs and cord blood purified CD34+ hematopoietic stem cells and electroporated the cells with the plasmids pT2-GFP and SB100x. As shown in figure 432 5A, the best electroporation score for MSC was obtained using buffer 2S, with 57% of 433 viable cells and 39% of GFP expression. When using SB100X, long-term expression of 434 GFP using this buffer was seen in 12% of cells (Fig. 5B ). For CD34+ cells, around 57% 435 were GFP-positive one day after electroporation using buffer 1SM and program U-008 436 (Fig. 6A) . These cells were plated in methylcellulose-based medium, allowing long-term 437 assessment of GFP expression and differentiation potential. After three weeks, GFP+ 438 CD34+ cells were able to differentiate to erythroid, granulocytic and myeloid lineages 439 (Fig. 6B) , showing that the insertion of the transgene did not affect the stemness of the 440 cells and that differentiated cells display high GFP expression ( Figure S17 ). (Fig. 7A) . A similar approach was performed in PBMCs and following electroporation, 480 indels were verified by amplification of PDCD1 locus of the edited cells, which was 481 subsequently cloned in pCR2.1 vector and analyzed by Sanger sequencing, evidencing 482 cells containing indels of varying lengths in the PDCD1 locus (Fig. 7B) . The results of Genetic modification of cells is a cumbersome and expensive process, often 520 involving the use of viral vectors to achieve high efficiency transgene expression. The 521 use of electroporation for the genetic modification of cells is being adopted by many 522 laboratories as it represents a fast and cheap option for transfer of plasmids and RNA.
523
Moreover, this technique is also very efficient, inducing transgene expression levels 524 comparable to viral vectors in some cells (Bilal et al., 2015) . basically every cell tested. Although we focused in Lonza´s device, it is likely that a 544 similar approach using these buffers in conjunction with electroporators that allow 545 modification of electroporation conditions could achieve even better results by fine tuning 546 parameters like pulse amplitude, voltage and wave forms (Yarmush et al., 2014) . Lonza`s 547 buffers were already described to have good results when tested with alternative nucleofector IIb programs (Gresch et al., 2004) , suggesting that there is still room for plasmid encoding Cas9+gRNA is simpler than constructing zinc finger nuclease (Beane Bonamino, M., Serafini, M., D'Amico, G., Gaipa, G., Todisco, E., Bernasconi, S., et al. Kuystermans, D., and Al-Rubeai, M. (2015) . 
